Quotient Clinical has been awarded three contracts for OncoADME programs to support clinical mass balance/ADME investigations in cancer patients. Two of the programs are for U.S.-based biopharma organizations and the third is for a top 10 global pharmaceutical company.   Quotient’s OncoADME service employs the company’s real-time adaptive manufacturing approach to supply 14C radiolabelled drug products to specialist oncology clinics globally. Drug products are manufactured on a ‘per patient’ bas...